<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170348</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS0396</org_study_id>
    <secondary_id>R01FD006372</secondary_id>
    <nct_id>NCT04170348</nct_id>
  </id_info>
  <brief_title>Daily Vitamin D for Sickle-cell Respiratory Complications</brief_title>
  <acronym>ViDAS-2</acronym>
  <official_title>Daily Vitamin D for Sickle-cell Respiratory Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary M Brittenham, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to answer the question whether daily oral vitamin D supplementation can
      reduce the risk of respiratory or lung complications in children and adolescents with sickle
      cell disease. Respiratory problems are the leading causes of sickness and of death in sickle
      cell disease. The investigators hypothesize that daily oral vitamin D3, compared to monthly
      oral vitamin D, will rapidly increase circulating vitamin D3, and reduce the rate of
      respiratory complications by 50% or more within the first year of supplementation in children
      and adolescents with sickle cell disease.

      This study is funded by the FDA Office of Orphan Products Development (OOPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-year controlled, double-blind, randomized Phase 2 clinical trial comparing the
      efficacy in reducing the rate of respiratory events in sickle-cell disease of daily oral
      vitamin D3 (3,333 IU/d) with monthly bolus oral vitamin D3, (100,000 IU/mo) as a control. The
      scientific premise of the clinical trial is that circulating concentrations of vitamin D3,
      the parent compound, are the principal determinant of the anti-infective and immunomodulatory
      effects of supplementation.

      Eligible participants will be initially screened to determine their blood vitamin D levels.
      Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be assigned by chance to
      one of the two arms for 24 months. Participants will be checked every month and will have
      periodic blood and urine tests to monitor for any side effects of the study treatments.
      Children above 5 y/o who can cooperate and understand the procedure will have lung function
      test once a year. Showing that a monthly dose of vitamin D reduces lung infections, asthma
      and the acute chest syndrome could help establish this simple, low-cost treatment as a way to
      decrease sickness and deaths in children and adolescents with sickle-cell disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Controlled, double-masked, randomized Phase 2 clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking will be performed by the Research Pharmacy; all other research staff and participants will be blinded to allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Respiratory Events</measure>
    <time_frame>Screening up to month 24</time_frame>
    <description>Annual rate of respiratory events will be calculated as the sum of respiratory infection, asthma exacerbation, and acute chest syndrome, as ascertained by use of a validated questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change forced vital capacity (FVC; % predicted) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Forced Expiratory Volume in 1 second (FEV1; % predicted) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity ratio</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Forced Expiratory Volume in 1 second (FEV1; % predicted)/Forced Vital Capacity (FVC) [FEV1/FVC] % predicted from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75) % predicted from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio of Residual Lung Volume (RV) to Total Lung Capacity (TLC)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in per cent of the ratio of Residual Lung Volume (RV) to Total Lung Capacity (RV/TLC) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO; % predicted) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fractional Concentration of Exhaled Nitric Oxide (FENO)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Fractional Concentration of Exhaled Nitric Oxide (FENO) in parts per billion (ppb) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Inspiratory Pressure (MIP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Maximum Inspiratory Pressure (MIP; cm H2O) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Expiratory Pressure (MEP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Maximum Expiratory Pressure (MEP; cm H2O) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 2 (IL 2) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 2 concentration (IL 2; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 4 (IL 4) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 4 concentration (IL 4; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 5 (IL 5) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 5 concentration (IL 5; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 13 (IL 13) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 13 concentration (IL 13; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interferon gamma (IFN gamma). concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interferon gamma concentration (IFN gamma; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 10 (IL 10) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 10 concentration (Iinterleukin 10; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Transforming Growth Factor beta (TGF beta)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum Transforming Growth Factor beta (TGF beta; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood hemoglobin concentration (Hb)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in blood hemoglobin concentration (Hb; g/dL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood platelet concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in blood platelet concentration (platelets/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-reactive protein (CRP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum C-reactive protein (CRP; mg/L) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 1alpha (IL 1alpha) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 1alpha (IL 1alpha; pg/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 1beta (IL 1beta) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 1beta (IL 1beta; pg/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor alpha (TNF alpha) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum Tumor Necrosis Factor alpha (TNF alpha; pg/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-terminal telopeptides of Type I collagen (CTX)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum C-terminal telopeptides of Type I collagen (CTX; ng/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intact N-terminal propeptide of type I procollagen (P1NP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Chang in serum intact N-terminal propeptide of type I procollagen (P1NP; Âµg/L) from baseline.=</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Anemia, Sickle Cell</condition>
  <condition>Anemia, Hemolytic, Congenital</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiration Disorders</condition>
  <condition>Acute Chest Syndrome</condition>
  <condition>Lung Diseases</condition>
  <condition>Asthma</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Nutrition Disorders</condition>
  <condition>Deficiency Diseases Vitamin</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Daily oral vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3, 3,333 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monthly bolus oral vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus oral vitamin D3, 100,000 IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily oral vitamin D3, 3,333 IU</intervention_name>
    <description>Oral vitamin D3, 3,333 IU, will be administered daily.</description>
    <arm_group_label>Daily oral vitamin D3</arm_group_label>
    <other_name>Cholecalciferol for oral administration</other_name>
    <other_name>10-secocholeta-5,7,10(19)-trien-3B-ol for oral administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bolus oral vitamin D3, 100,000 IU</intervention_name>
    <description>Bolus oral vitamin D3, 100,000 IU, will be administered monthly.</description>
    <arm_group_label>Monthly bolus oral vitamin D3</arm_group_label>
    <other_name>Cholecalciferol for oral administration</other_name>
    <other_name>10-secocholeta-5,7,10(19)-trien-3B-ol for oral administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.</description>
    <arm_group_label>Monthly bolus oral vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of sickle cell disease (Hb SS, Hb SC, Hb S-Beta-thalassemia)

          2. Age 3-20 years old

        Exclusion Criteria:

          1. Patient unwilling or unable to provide written informed consent (and assent, if
             applicable)

          2. Patient unable or unwilling to comply with requirements of the clinical trial

          3. Participation in another clinical trial

          4. Current diagnosis of rickets

          5. History of hypercalcemia or diagnosis of any medical condition associated with
             hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis,
             tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia

          6. Current use of corticosteroids, excluding inhaled steroids

          7. Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)

          8. Therapy with thiazide diuretics or lithium carbonate

          9. Known liver or renal disease

         10. Patients taking medications for pulmonary complications of sickle cell disease not on
             a stable dose of medications, as defined by a change in medications or doses within
             the three months prior to study entry

         11. Patients on chronic red blood cell transfusion therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary M Brittenham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret T Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary M Brittenham, MD</last_name>
    <phone>212 305 7005</phone>
    <email>gmb31@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret T Lee, MD</last_name>
    <phone>212 305 6290</phone>
    <email>ml653@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Margaret T Lee, MD</last_name>
      <phone>212-305-6290</phone>
      <email>ml653@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Miriam Rosen</last_name>
      <phone>646 317 2070</phone>
      <email>mr3989@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen M Arpadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilene Fennoy, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhezhen Jin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meyer Kattan, MD, CM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeri Nieves, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bloodadvances.org/content/2/9/969.long?sso-checked=true</url>
    <description>Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease.</description>
  </link>
  <link>
    <url>https://journals.lww.com/jpho-online/Abstract/2018/08000/Response_to_Long_term_Vitamin_D_Therapy_for_Bone.8.aspx</url>
    <description>Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease.</description>
  </link>
  <reference>
    <citation>Lee MT, Kattan M, Fennoy I, Arpadi SM, Miller RL, Cremers S, McMahon DJ, Nieves JW, Brittenham GM. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Adv. 2018 May 8;2(9):969-978. doi: 10.1182/bloodadvances.2017013979.</citation>
    <PMID>29712666</PMID>
  </reference>
  <reference>
    <citation>Williams KM, Lee MT, Licursi M, Brittenham GM, Fennoy I. Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2018 Aug;40(6):458-461. doi: 10.1097/MPH.0000000000001155.</citation>
    <PMID>29668535</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Gary M Brittenham, MD</investigator_full_name>
    <investigator_title>James A. Wolff Professor of Pediatrics and Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Acute Chest Syndrome</keyword>
  <keyword>Respiratory Complication</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Acute Chest Syndrome</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Congenital</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Vitamin A Deficiency</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Trientine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

